The galactose elimination capacity and mortality in 781 Danish patients with newly-diagnosed liver cirrhosis: A cohort study

BMC Gastroenterology

Volumn 9, Issue , 2009, Pages

  Jepsen, Peter ^a   Vilstrup, Hendrik ^a   Ott, Peter ^a   Keiding, Susanne ^a   Andersen, Per K ^b   Tygstrup, Niels ^c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GALACTOSE;

ALCOHOL LIVER CIRRHOSIS; ARTICLE; ATHEROSCLEROSIS; BLOOD LEVEL; COHORT ANALYSIS; COMORBIDITY; DIABETES MELLITUS; FEMALE; GALACTOSE ELIMINATION CAPACITY; HUMAN; LIVER CIRRHOSIS; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC CAPACITY; MORTALITY; NONALCOHOLIC FATTY LIVER; SEX DIFFERENCE; ULCER; URINARY EXCRETION; DENMARK; FOLLOW UP; LIVER; METABOLISM; MIDDLE AGED; PREDICTION AND FORECASTING; REGISTER; REGRESSION ANALYSIS; RETROSPECTIVE STUDY;

COHORT STUDIES; DENMARK; FEMALE; FOLLOW-UP STUDIES; GALACTOSE; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REGISTRIES; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES;

EID: 68949209177     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-9-50     Document Type: Article

References (33)

1. Sørensen HT Thulstrup AM Mellemkjar L Jepsen P Christensen E Olsen JH Vilstrup H Long-term survival and cause-specific mortality in patients with cirrhosis of the liver: A nationwide cohort study in Denmark J Clin Epidemiol 2003, 56:88-93. 10.1016/S0895-4356(02)00531-0 12589875
2. Christensen E Prognostic models including the Child-Pugh, MELD and Mayo risk scores - where are we and where should we go? J Hepatol 2004, 41:344-350. 10.1016/j.jhep.2004.06.005 15288486
3. Tygstrup N Assessment of liver function - principles and practice J Gastroenterol Hepatol 1990, 5:468-482. 10.1111/ j.1440-1746.1990.tb01426.x 2129819
4. Molino G The functioning liver mass Res Clin Lab 1991, 21:9-40. 10.1007/ BF02919112
5. Schmidt LE Ott P Tygstrup N Galactose elimination capacity as a prognostic marker in patients with severe acetaminophen-induced hepatotoxicity: 10 years' experience Clin Gastroenterol Hepatol 2004, 2:418-424. 10.1016/S1542-3565(04)00128-4 15118981
6. Salerno F Borroni G Moser P Sangiovanni A Almasio P Budillon G Capuano G Muraca M Marchesini G Bernardi M Marenco G Molino G Rossaro L Solinas A Ascione A Carpinelli L Politi F diCostanzo GG Boselli L Trevisani F Fabbri A Sama C Giudici A Ponassi I diNapoli A Avagnina P Niro AG Deplano A Fabris L Iemmolo RM Eko G Salvagnini M Prognostic value of the galactose test in predicting survival of patients with cirrhosis evaluated for liver transplantation - a prospective multicenter Italian study J Hepatol 1996, 25:474-480. 10.1016/S0168-8278(96)80206-6 8912146
7. Merkel C Gatta A Zoli M Bolognesi M Angeli P Iervese T Marchesini G Ruol A Prognostic value of galactose elimination capacity, aminopyrine breath test, and ICG clearance in patients with cirrhosis. Comparison with the Pugh score Dig Dis Sci 1991, 36:1197-1203. 10.1007/BF01307508 1893804
8. Merkel C Bolognesi M Angeli P Noventa F Caregaro L Sacerdoti D Gatta A Prognostic indicators of survival in patients with cirrhosis and esophageal varices, without previous bleeding Am J Gastroenterol 1989, 84:717-722. 2787099
9. Albers I Hartmann H Bircher J Creutzfeldt W Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis Scand J Gastroenterol 1989, 24:269-276. 10.3109/00365528909093045 2734585
10. Zoli M Cordiani MR Marchesini G Iervese T Labate AM Bonazzi C Bianchi G Pisi E Prognostic indicators in compensated cirrhosis Am J Gastroenterol 1991, 86:1508-1513. 1928047
11. Addario L Scaglione G Tritto G Di Costanzo GG De Luca M Lampasi F Galeota Lanza A Picciotto FP Teresa Tartaglione M Utech W Macri M Giannelli E Ascione A Prognostic value of quantitative liver function tests in viral cirrhosis: A prospective study Eur J Gastroenterol Hepatol 2006, 18:713-720. 10.1097/01.meg.0000219104.40435.43 16772827
12. Garello E Battista S Bar F Niro GA Cappello N Rizzetto M Molino G Evaluation of hepatic function in liver cirrhosis: Clinical utility of galactose elimination capacity, hepatic clearance of D-sorbitol, and laboratory investigations Dig Dis Sci 1999, 44:782-788. 10.1023/ A:1026678228967 10219839
13. Tygstrup N The galactose elimination capacity in relation to clinical and laboratory findings in patients with cirrhosis Acta Med Scand 1964, 175:291-300. 14136244
14. Marchesini G Bua V Brunori A Bianchi G Pisi P Fabbri A Zoli M Pisi E Galactose elimination capacity and liver volume in aging man Hepatology 1988, 8:1079-1083. 10.1002/hep.1840080516 3417228
15. Schnegg M Lauterburg BH Quantitative liver function in the elderly assessed by galactose elimination capacity, aminopyrine demethylation and caffeine clearance J Hepatol 1986, 3:164-171. 10.1016/ S0168-8278(86)80022-8 3794298
16. Tygstrup N The galactose elimination capacity in control subjects and in patients with cirrhosis of the liver Acta Med Scand 1964, 175:281-289. 14136243
17. Jepsen P Vilstrup H Andersen PK Lash TL Sørensen HT Comorbidity and survival of Danish cirrhosis patients: A nationwide population-based cohort study Hepatology 2008, 48:214-220. 10.1002/hep.22341 18537190
18. Tygstrup N Determination of hepatic elimination capacity (Lm) of galactose by single injection Scand J Clin Lab Invest Suppl 1966, 18:118-125. 5958511
19. Tygstrup N Effect of sites of blood sampling in determination of the galactose elimination capacity Scand J Clin Lab Invest 1977, 37:333-338. 10.3109/00365517709092638 616060
20. Andersen TF Madsen M Jørgensen J Mellemkjær L Olsen JH The Danish National Hospital Register. A valuable source of data for modern health sciences Dan Med Bull 1999, 46:263-268. 10421985
21. Charlson ME Pompei P Ales KL MacKenzie CR A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation J Chronic Dis 1987, 40:373-383. 10.1016/0021-9681(87)90171-8 3558716
22. Frank L When an entire country is a cohort Science 2000, 287:2398-2399. 10.1126/science.287.5462.2398 10766613
23. Cleveland WS Robust locally weighted regression and smoothing scatterplots J Am Stat Assoc 1979, 74:829-836. 10.2307/2286407
24. Kalbfleisch JD Prentice RL Estimation of the average hazard ratio Biometrika 1981, 68:105-112. 10.1093/biomet/68.1.105
25. Marubini E Valsecchi MG Competing risks Analysing survival data from clinical trials and observational studies Chichester, UK: John Wiley & Sons 1 1995:331-363.
26. Lindskov J The quantitative liver function as measured by the galactose elimination capacity. II. Prognostic value and changes during disease in patients with cirrhosis Acta Med Scand 1982, 212:303-308. 7180580
27. Merkel C Marchesini G Fabbri A Bianco S Bianchi G Enzo E Sacerdoti D Zoli M Gatta A The course of galactose elimination capacity in patients with alcoholic cirrhosis: Possible use as a surrogate marker for death Hepatology 1996, 24:820-823. 10.1002/hep.510240412 8855183
28. Almdal TP Sørensen TI Incidence of parenchymal liver diseases in Denmark, 1981 to 1985: Analysis of hospitalization registry data Hepatology 1991, 13:650-655. 10.1002/hep.1840130407 2010159
29. World Health Organization Hepatitis C - global prevalence (update) Wkly Epidemiol Rec 1999, 74:425-427. 10645164
30. Nelsing S Wantzin P Skot J Krarup E Nielsen TL Krarup HB Nielsen JO The seroprevalence of hepatitis B and C in hospitalized Danish patients Scand J Infect Dis 1995, 27:445-448. 10.3109/00365549509047043 8588132
31. Vestberg K Thulstrup AM Sørensen HT Ottesen P Sabroe S Vilstrup H Data quality of administratively collected hospital discharge data for liver cirrhosis epidemiology J Med Syst 1997, 21:11-20. 10.1023/ A:1022835207287 9172066
32. Fabbri A Bianchi G Motta E Brizi M Zoli M Marchesini G The galactose elimination capacity test: A study of the technique based on the analysis of 868 measurements Am J Gastroenterol 1996, 91:991-996. 8633594
33. Lotterer E Högel J Gaus W Fleig WE Bircher J Quantitative liver function tests as surrogate markers for end-points in controlled clinical trials: A retrospective feasibility study Hepatology 1997, 26:1426-1433. 10.1002/hep.510260609 9397982